secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cocrystal Pharma, Inc. (COCP)
CIK:        0001412486
Form:       8-K
Filed at:   2026-02-19T23:59:59+00:00
Accession:  0001493152-26-007430
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cocrystal Pharma's CDI-988 oral norovirus inhibitor to be featured at ICAR 2026
-------------------------------------------------------------------------------

- CDI-988 is the first oral antiviral drug candidate developed for prevention and treatment of norovirus infections.
- Company to present Phase 1b challenge study data at ICAR 2026 in Prague (Apr 27-May 1, 2026).
- No approved antiviral therapies or vaccines for norovirus; estimated $10.6B annual US economic burden.
- CDI-988 is a pan-viral protease inhibitor also targeting coronaviruses, developed using proprietary structure-based platform.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1412486/000149315226007430/0001493152-26-007430-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1412486/000149315226007430/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-007430

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer